Raajmarg Infra Investment Trust IPO...
05 Mar, 2026
Curis Lifesciences IPO
Curis Lifesciences Ltd is ready to launch its SME IPO on NSE Emerge from 7th November 2025 to 11th November 2025. It is a fresh issue of 0.22 crore shares worth ₹27.52 crore, with a price band of ₹120 to ₹128 per share. The face value per share is ₹10 per share. The tentative listing date of Curis Lifesciences IPO is 14th November 2025.
The lot size of the application is 1,000, with the minimum investment amount required by an individual investor (retail) at ₹2,56,000 (2,000 shares) based on the upper price and the minimum lot size investment is of 3 lots (3,000 shares), which is ₹3,84,000. Finaax Capital Advisors Pvt Ltd is the lead manager and MUFG Intime India Pvt Ltd is the registrar of the issue. RS Wealth Management Pvt Ltd is the Market Maker of this IPO.
Company Background
Curis Lifesciences Limited is a public limited company that was originally incorporated as Curis Lifesciences Private Limited in 2016 and was later converted into a public entity on 6th May 2024. This company is based in Ahmedabad, Gujarat and is involved in the manufacturing and marketing of medicines which include tablets, capsules, ointments, and creams.
The company focuses on maintaining high quality in its products and keeping them affordable for patients.
Operations And Product Range
Curis Lifesciences Ltd operates in advanced R&D and manufacturing facilities using modern biotechnology and pharmaceutical processes, which help create drug intermediates and research chemicals. It sells its products primarily through contracts with pharma companies and research centers.
Revenue Channels
Curis Lifesciences Ltd generates revenue by selling specialized drug ingredients to biotech and research institutions. It also provides custom products and research materials to the institutes. Apart from this, they export the products to international customers. The company reported revenue of ₹49.65 crore in FY 2025.
Management And Shareholding
The promoters of the Curis Lifesciences IPO include Dharmesh Dashrathbhai Patel, Siddhant Jayantibhai Pawasia, Piyush Gordhanbhai Antala, and Jaimik Mansukhbhai Patel. They hold the major share of the company’s equity, which reflects their deep involvement and long-term commitment to growth.
WHAT IS GMP?
GMP (Grey Market Premium) is the difference between the IPO price and the grey market price. It is the premium amount paid for the traded IPO shares. It plays an important role in IPOs as it reflects how the IPO would react on the listing day.
A grey market is a place where shares/stocks are traded before being listed officially on the stock exchange.
Curis Lifesciences IPO GMP
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| - | - | - | - |
**The GMP prices displayed here are solely for informational purposes related to the grey market news. India IPO does not engage in or facilitate grey market trading, nor are these rates (sub2) indicative of any trading activity. We also do not recommend or endorse participation in the grey market.**
Curis Lifesciences IPO Details
| Detail | Description |
|---|---|
| IPO Date | 7th November 2025 - 11th November 2025 |
| Listing Date | [.] |
| Face Value | ₹10 Per Share |
| Issue Price Band | ₹120 - ₹128 Per Share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 21,50,000 Shares (aggregating upto 27.52cr) |
| Reserved for Market Maker | 1,08,000 Shares (aggregating upto 1.3 cr) RS Wealth Management Private Ltd |
| Fresh Issue(Ex Market Maker) | 20,42,000 Shares (aggregating up to 26.14 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 59,34,434 Shares |
| Share Holding Post Issue | 80,84,434 Shares |
Curis Lifesciences IPO Timeline
| Detail | Description |
|---|---|
| IPO Open Date | 7th November 2025 |
| IPO Close Date | 11th November 2025 |
| Tentative Allotment | 12th November 2025 |
| Initiation of Refunds | 13th November 2025 |
| Credit of Shares to Demat | 13th November 2025 |
| Tentative Listing Date | 14th November 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on 11th November 2025 |
Curis Lifesciences IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,56,000 |
| Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,56,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,84,000 |
| S-HNI (Max) | 7 | 7,000 | ₹8,96,000 |
| B-HNI (Min) | 8 | 8,000 | ₹10,24,000 |
Curis Lifesciences IPO Promoter Holding
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| Promoter Holding Pre Issue | 92.68% |
| Promoter Holding Post Issue | 68.03% |
Competitive Strength:
- • Curis Lifesciences manufactures a wide range of pharmaceutical formulations which include tablets, capsules, syrups and ointments for multiple segments.
- • It has a strong manufacturing base in Ahmedabad and is growing domestically.
- • For the past few years, it has shown steady growth in revenue and profitability with an increase in demand for healthcare products and manufacturing services.
Curis Lifesciences IPO Financial Information
| Period Ended | Assets | Total Income | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 July 2025 | 56.29 | 19.51 | 2.87 | 19.10 | - | 15.32 | ||||||||||||||||||||||||||||||||||
| 31 March 2025 | 42.53 | 49.65 | 6.11 | 16.23 | - | 15.62 | ||||||||||||||||||||||||||||||||||
| 31 March 2024 | 33.88 | 35.87 | 4.87 | 5.87 | - | 17.09 | ||||||||||||||||||||||||||||||||||
| 31 March 2023 | 29.75 | 36.42 | 1.88 | 1.01 | - | 16.19 | ||||||||||||||||||||||||||||||||||
| Amount in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||
Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 55.25% |
| ROCE | 27.83% |
| Debt/Equity | 0.96 |
| RoNW | 37.62% |
| PAT Margin | 12.43% |
| EBITDA Margin | 19.41% |
| Price to Book Value | 12.64 |
| Market Capitalization | 103.48 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 10.29 | 10.66 |
| P/E (x) | 12.44 | 12.01 |
IPO Objectives of Curis Lifesciences IPO
The company proposes to utilize the IPO Net Proceeds towards the following objects:
- • Working capital requirements (₹2.44 crore) towards Upgradation/Improvement of the existing manufacturing facilities.
- • Capital expenditure requirements (₹3.62 crore) towards the construction of a storage facility.
- • Funding of the amount (₹11.25 crore) for the working capital requirements.
- • Prepayment or repayment of outstanding secured loans (₹1.86 crore).
- • The company proposes to utilize ₹2.69 crore for the registration of its products in other countries.
Conclusion
Curis Lifesciences IPO offers a lucrative opportunity for investors to invest in a reputed, growing pharmaceutical company that enjoys a strong presence in manufacturing a wide range of formulations like tablets, capsules, ointments, and syrups. Backed by a robust manufacturing base in Ahmedabad, the company is characterized by steady revenue and profit growth and is well-positioned to meet increasing healthcare demands in India and beyond.
The fresh capital raised through Curis Lifesciences IPO is expected to be used for upgrading manufacturing facilities, expanding storage capacity, supporting working capital needs, repaying debt, and funding international product registrations to strengthen operational capabilities and support future growth.
The IPO, priced between ₹120 and ₹128 per share, will list on NSE SME with a tentative listing date fixed as November 14, 2025. It has a book build issue of ₹27.52 crores, and the issue is entirely a fresh issue of 0.22 crore shares worth ₹27.52 crore.
Overall, the Curis Lifesciences IPO blends growth potential with focused deployment of funds and operational strength, making it an attractive consideration for investors seeking participation in the pharma space for the long term.
RHP:
View RHPDRHP:
View DRHPRead more :
Frequently Asked Questions (FAQs)
-
When does Curis Lifesciences Ltd IPO open and close?
The IPO of Curis Lifesciences Ltd. opens on November 7, 2025 and closes on November 11, 2025.
-
What is the total size of the IPO?
The issue size for the Curis Lifesciences IPO is ₹27.52 crore through a fresh issue of 0.22 crore shares, with total shares being offered standing at 6,10,000.
-
Where will the IPO be listed?
The IPO will be listed on the NSE SME platform.
-
What are the primary objectives for the Curis Lifesciences Ltd. IPO proceeds?
The primary objectives for the Curis Lifesciences IPO proceeds include Capital Expenditure towards the Upgradation/Improvement of the existing Manufacturing Facilities and the Construction of a Storage Facility. It also includes Pre-payment/Repayment of outstanding Secured Loans, Product Registrations in other countries and funding its Working Capital Requirements.
